MidFirst Bank’s Charles River Laboratories CRL Stock Holding History

MidFirst Bank’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$227	Hold	1	–	–	﹤0.01%	897
2026 Q1	$173	Buy	+1	New	+$185	﹤0.01%	886

Other funds holding CRL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MidFirst Bank's CRL Position: Q2 2026 in Review

MidFirst Bank held its Charles River Laboratories (CRL) position steady in Q2 2026 at 1 share worth $227. The position accounts for ﹤0.01% of the portfolio, ranked #897.

MidFirst Bank first reported a position in CRL in Q1 2026 and has held it in 2 quarters since. 436 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

MidFirst Bank held 1 share of Charles River Laboratories worth $227 as of Q2 2026.
MidFirst Bank left its Charles River Laboratories share count unchanged in Q2 2026.
Charles River Laboratories made up ﹤0.01% of MidFirst Bank's portfolio in Q2 2026, its #897 holding.
MidFirst Bank first reported a position in Charles River Laboratories in Q1 2026 and has held it in 2 quarters since.
436 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on MidFirst Bank's 13F filing for Q2 2026, filed 7 Aug 2026.